Oncotarget

Research Papers:

Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme

Yvonne Becker, Sarah Förster, Gerrit H. Gielen, Ian Loke, Morten Thaysen-Andersen, Christine Laurini, Kristin Wehrand, Torsten Pietsch and Simone Diestel _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:4449-4465. https://doi.org/10.18632/oncotarget.27056

Metrics: PDF 4 views  |   HTML 12 views  |   ?  


Abstract

Yvonne Becker1,*, Sarah Förster1,*, Gerrit H. Gielen2, Ian Loke3, Morten Thaysen-Andersen3, Christine Laurini1, Kristin Wehrand1, Torsten Pietsch2 and Simone Diestel1

1 Institute of Nutrition and Food Sciences, Department of Human Metabolomics, University of Bonn, Bonn 53115, Germany

2 Institute of Neuropathology, University of Bonn Medical Center, Bonn 53127, Germany

3 Department of Molecular Sciences, Macquarie University, Sydney, NSW 2109, Australia

* These authors contributed equally to this work

Correspondence to:

Simone Diestel,email: s.diestel@uni-bonn.de

Keywords: cancer progression; glioblastoma multiforme; N-glycosylation; paucimannosidic epitopes; AHNAK

Received: April 05, 2019     Accepted: June 10, 2019     Published: July 09, 2019

ABSTRACT

Glioblastoma multiforme is an aggressive cancer type with poor patient outcomes. Interestingly, we reported previously a novel association between the little studied paucimannosidic N-linked glycoepitope and glioblastoma. Paucimannose has only recently been detected in vertebrates where it exhibits a very restricted tumor-specific expression. Herein, we demonstrate for the first time a very high protein paucimannosylation in human grade IV glioblastoma and U-87MG and U-138MG glioblastoma cells. Furthermore, we revealed the involvement of paucimannosidic epitopes in tumorigenic processes including cell proliferation, migration, invasion and adhesion. Finally, we identified AHNAK which is discussed as a tumor suppressor as the first paucimannose-carrying protein in glioblastoma and show the involvement of AHNAK in the observed paucimannose-dependent effects. This study is the first to provide evidence of a protective role of paucimannosylation in glioblastoma, a relationship that with further in vivo support may have far reaching benefits for patients suffering from this often fatal disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27056